Head-To-Head Review: IDEXX Laboratories (NASDAQ:IDXX) vs. Delcath Systems (NASDAQ:DCTH)

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Valuation and Earnings

This table compares IDEXX Laboratories and Delcath Systems”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $4.66 billion 11.87 $1.06 billion $14.83 47.37
Delcath Systems $109.96 million 6.24 $2.70 million $0.16 123.25

IDEXX Laboratories has higher revenue and earnings than Delcath Systems. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for IDEXX Laboratories and Delcath Systems, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories 0 6 7 0 2.54
Delcath Systems 0 1 2 1 3.00

IDEXX Laboratories currently has a consensus target price of $717.27, indicating a potential upside of 2.11%. Delcath Systems has a consensus target price of $29.33, indicating a potential upside of 48.75%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than IDEXX Laboratories.

Institutional & Insider Ownership

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares IDEXX Laboratories and Delcath Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IDEXX Laboratories 25.36% 71.04% 33.99%
Delcath Systems 6.05% 5.56% 4.98%

Volatility and Risk

IDEXX Laboratories has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Summary

IDEXX Laboratories beats Delcath Systems on 10 of the 15 factors compared between the two stocks.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.